~~~BREAKING NEWS – FDA’s announcement ahead of schedule~~~
The great fall of a long pursuit
As expected, Mannkind got rejected AGAIN! The FDA handed out a complete response letter to the developer of Afrezza, an inhaled form of insulin, requesting additional information regarding the performance characteristics, usage, handling, shipment and storage of the next-generation device, an update of safety information related to AFREZZA . The agency also wanted to obtain information on proposed user training and changes to the proposed labeling of the device, blister pack, foil wrap and cartons. Two additional clinical trials may also be requested.
Why couldn’t I purchase the options you suggested?
Mannkind’s stock was down ~32% in early trading before settling at $9.11 (-7.32%). All trading activities were suspended and halted by the SEC for investigation into potential errors in the system. The suspension included all shares and options and that’s why no one was able to trade after around 11:58 am ET.
No comments:
Post a Comment